Literature DB >> 31856541

Commentary: Internal limiting membrane sparing in necrotizing focal retinitis.

Mohit Dogra1, Simar Rajan Singh1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 31856541      PMCID: PMC6951161          DOI: 10.4103/ijo.IJO_2204_19

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


× No keyword cloud information.
Necrotizing focal retinitis is a vision-threatening condition which can lead to fulminant loss of vision if not managed promptly. The etiology for the same can be either infective or autoimmune, with infective causes forming the major chunk of the cases in India.[1] With the advent of high-resolution optical coherence tomography (OCT), newer insights are being provided into the pattern and extent of retinal involvement in various causes of retinitis. In the current issue, Babu et al. presents a case of acquired toxoplasma retinitis with serial OCT documentation of the course of retinitis.[2] They describe the findings of “bridge sign” on OCT in toxoplasma retinitis. The “bridge” is essentially the spared internal limiting membrane (ILM) in the area of the full thickness retinitis “bridging” between the surrounding healthy retinas. While being well-documented, this finding of ILM sparing is not unique to toxoplasma retinitis. It has been characteristically described in retinitis associated with subacute sclerosing panencephalitis (SSPE).[3] The classic presentation in SSPE is bilateral sequential involvement of the posterior pole with rapid necrolysis of the neurosensory retina and sparing of the ILM. The quantum and rapidity of visual loss is often striking and is rarely seen in any other form of posterior necrotizing focal retinitis. Viral retinitis, secondary to herpes viruses like varicella-zoster virus (VZV), herpes simplex virus (HSV), and cytomegalovirus (CMV) may also present with a similar finding of full-thickness retinitis with progressive loss of retinal layers and sparing of the ILM.[14] The ILM has been postulated as the third retinal barrier after the tight junctions of the retinal pigment epithelium (RPE) and the retinal capillaries.[5] This could be a possible explanation of the sparing of the ILM and limiting of the necrosis to the retina. In the natural course, the ILM bridge eventually crumbles over the retinal pigment epithelium leading to complete effacement of the retinal architecture. In conclusion, ILM sparing on OCT is essentially a sign of rapidly progressive, full-thickness necrotizing retinitis. Its presence should prompt us to think in terms of infective etiology and tailored investigations should be ordered to rule out SSPE, toxoplasmosis, and herpes viruses like HSV, VZV, and CMV.
  5 in total

1.  Spectrum of Newly Diagnosed Cytomegalovirus Retinitis in a Developing Country in the HAART Era.

Authors:  Simar Rajan Singh; Mohit Dogra; Savleen Kaur; Priya Bajgai; Basavaraj Tigari; Sabia Handa; Deeksha Katoch; Vishali Gupta; Mangat R Dogra; Aman Sharma; Ramandeep Singh
Journal:  Ocul Immunol Inflamm       Date:  2018-11-05       Impact factor: 3.070

2.  Internal limiting membrane: The innermost retinal barrier.

Authors:  Rohan Chawla; Koushik Tripathy; Shreyas Temkar; Vinod Kumar
Journal:  Med Hypotheses       Date:  2016-11-25       Impact factor: 1.538

3.  BILATERAL SUBRETINAL FLUID AND RETINAL VASCULOPATHY ASSOCIATED WITH SUBACUTE SCLEROSING PANENCEPHALITIS.

Authors:  Aniruddha Agarwal; Ramandeep Singh; Abiraj Kumar; Mangat R Dogra; Amod Gupta
Journal:  Retin Cases Brief Rep       Date:  2017 Spring

4.  Near full thickness macular hole with an intact overlying internal limiting membrane following resolution of fulminant acquired toxoplasma retinitis -A unique finding.

Authors:  Kalpana Babu; Dhwani Shah; M Bhagya; Krishna R Murthy
Journal:  Indian J Ophthalmol       Date:  2020-01       Impact factor: 1.848

5.  An imaging-based treatment algorithm for posterior focal retinitis.

Authors:  Rohan Chawla; Koushik Tripathy; Shreyas Temkar; Pradeep Venkatesh; Atul Kumar
Journal:  Ther Adv Ophthalmol       Date:  2018-04-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.